RxDoctor Payments Data

Keisha Ritter

Family · Brandywine, MDNPI 1750784419

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,966 of the $12,397 with a category attached, or 80.4%. It is spread thinly across 60 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,451, 4.8 times the $718 reported in 2021. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,397in general payments, 2019–2025

Across 461 payments — averaging $26.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • AstraZeneca$784
  • Johnson & Johnson$762
  • Merck$640
  • Pfizer$626
  • Incyte Corporation$493
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$9,96680%
  • Education$6525%
  • Other$1,78014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,397 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$128,012
Medicare patients
98
Services billed
4,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban110$89,192
XareltoRivaroxaban30$46,762
Enoxaparin Sodium14$3,568
Acyclovir21$576
Hydroxyurea22$475
Warfarin Sodium61$441
Morphine Sulfate ErMorphine Sulfate11$429
Anastrozole22$378
Letrozole13$273
Omeprazole12$227
Bicalutamide11$187
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$153
Prednisone14$131
Dexamethasone13$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$626$89,192110 claims
Johnson & JohnsonXarelto$762$46,76230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.

Other family in Brandywine

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →